A Phase 1, Dose Escalation, Safety and Tolerability Study of NX-2127, a Bruton's Tyrosine Kinase (BTK) Degrader, in Adults With Relapsed/Refractory B-cell Malignancies
This is a first-in-human Phase 1a/1b multicenter, open-label oncology study designed to evaluate the safety and anti-cancer activity of NX-2127 in patients with advanced B-cell malignancies.
Indication: Chronic Lymphocytic Leukemia (CLL)
Modality: small molecule
Target: NX-2127
Sponsor: Nurix Therapeutics, Inc.
Source URL: ClinicalTrials.gov
Source updated: Mar 20, 2026
Ingested: Jun 05, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: NX-2127
View original source fields
Condition raw: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Condition normalized: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL), Waldenstrom Macroglobulinemia (WM), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Follicular Lymphoma (FL), Diffuse Large B-cell Lymphoma (DLBCL), Primary Central Nervous System Lymphoma (PCNSL)
Modality raw: small molecule
Modality normalized: small molecule
Target raw: NX-2127
Target normalized: NX-2127